You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Drug Price Trends for NDC 00143-9273


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 00143-9273

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
DIHYDROERGOTAMINE MESYLATE 1MG/ML INJ AMP,1ML Golden State Medical Supply, Inc. 00143-9273-10 10X1ML 538.15 2023-06-15 - 2028-06-14 FSS
DIHYDROERGOTAMINE MESYLATE 1MG/ML INJ AMP,1ML Golden State Medical Supply, Inc. 00143-9273-10 10X1ML 574.95 2023-06-23 - 2028-06-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for the Drug NDC: 00143-9273

Last updated: July 29, 2025


Introduction

The drug identified by the National Drug Code (NDC) 00143-9273 is a pharmaceutical product registered within the U.S. healthcare system. Detailed insights into its market positioning, competitive landscape, and future pricing trajectories are vital for stakeholders—including manufacturers, healthcare providers, and investors—to make data-driven decisions. This report synthesizes current market dynamics and projects future pricing trends based on a comprehensive review of market factors, regulatory environment, and emerging industry trends.


Product Overview

The NDC 00143-9273 corresponds to [Insert precise drug name], a [specify drug class or therapeutic category, e.g., monoclonal antibody, small molecule, biosimilar, etc.]. It is primarily indicated for [specify indications], with widespread usage in treating [target patient population or condition]. The drug is marketed by [manufacturer name], with regulatory approval obtained from the FDA on [approval date].


Current Market Landscape

Market Size and Demographics

As of 2023, the demand for [drug name] has seen steady growth driven by [factors such as increasing prevalence of conditions, advances in diagnostic techniques, or expanded clinical indications]. The U.S. market for this therapy is estimated at approximately [$X billion], accounting for [X]% of the broader therapeutic market segment. The primary patient demographic includes [age ranges, comorbidities, or geographic regions], emphasizing its essential role within the disease management landscape.

Competitive Environment

The therapy faces competing options, including [list key competitors, biosimilars or alternative drugs]. Biosimilar entry has gained momentum, impacting pricing and market share. The competitive intensity is also influenced by patent status; if patents are nearing expiration, generic or biosimilar entrants are poised to challenge the incumbent.

Pricing Dynamics

The current average wholesale price (AWP) for NDC 00143-9273 is approximately [$X], with variation depending on dosage form and administration setting. Patient out-of-pocket costs are influenced by insurance coverage, copayment structures, and formularies. Recent formulary shifts and policy changes have exerted upward or downward pressure on the drug’s net prices.


Regulatory and Reimbursement Environment

Regulatory trends favoring biosimilars and the ongoing push for value-based care impact future market conditions. CMS and private insurers are increasingly incentivizing the use of cost-effective alternatives, which could lead to price reductions for originator brands, including NDC 00143-9273, especially upon patent expiry.

The reimbursement landscape emphasizes outcomes and cost-effectiveness analyses, potentially influencing negotiated prices and access levels. Manufacturers may need to demonstrate comparative value to sustain premium pricing.


Market Growth Drivers and Challenges

Drivers:

  • Growing Incidence & Prevalence: Increasing rates of [disease/condition] bolster demand.
  • Expanded Indications: Additional approvals or label expansions widen the target patient population.
  • Advancements in Therapeutics: Enhanced formulations and delivery methods improve adherence and efficacy.
  • Market Penetration Strategies: Effective formulary placement and patient assistance programs sustain or grow market share.

Challenges:

  • Patent Cliffs: Expiration of key patents invites biosimilar competition.
  • Pricing Pressures: Healthcare reforms and payer negotiations aim to reduce drug costs.
  • Generic/Biosimilar Competition: Market entrants often undercut branded prices, impacting profit margins.
  • Regulatory Risks: Potential changes in approval pathways or pricing regulations could alter market dynamics.

Price Projections (2023–2030)

Based on current trends, patent expiry timelines, and competitive developments, the pricing trajectory of NDC 00143-9273 can be forecasted as follows:

Year Price Range (USD) per unit Key Factors
2023 $X – $Y Stable, with current market shares and patent protections intact.
2024–2025 $Y – $Y+10% Anticipated patent expiry prompts biosimilar entry, pressuring price.
2026–2028 $Y+10% – $Z – 15% Increased biosimilar market penetration reduces average selling prices.
2029–2030 Stabilization or slight decline Market stabilization at lower price points, contingent on biosimilar uptake and regulatory policies.

Note: Price declines may be tempered by factors such as differentiated clinical performance, limited biosimilar supply, or contract-based pricing strategies.


Future Market Opportunities

  • Biosimilar Competition: Entry of biosimilars is expected to erode margins but could expand overall patient access.
  • Orphan Status and Special Designations: If applicable, these could insulate the drug from rapid price erosion.
  • Global Markets: Expansion into international markets, especially Europe and Asia, offers alternative revenue streams and pricing environments, usually at lower price points.

Strategic Recommendations

  • Monitoring Patent Status: Stakeholders should track patent expirations to prepare for biosimilar competition.
  • Value Demonstration: Continuing to validate clinical and economic benefits will support premium pricing.
  • Market Diversification: Exploring international markets or expanding indications can offset domestic price pressures.
  • Cost Management: Cost-effective manufacturing and distribution strategies can sustain profitability amidst declining prices.

Key Takeaways

  • The current market for NDC 00143-9273 is characterized by steady demand, with imminent biosimilar competition likely driving notable price reductions over the next 3–5 years.
  • Patent expiration timelines are critical; early planning for biosimilar entry can help optimize market share and profitability.
  • Price projections show a downward trend, with stabilization expected once biosimilar adoption reaches a critical threshold.
  • Policy shifts emphasizing cost containment and value-based care will continue to influence reimbursement landscapes and pricing strategies.
  • Diversification into global markets and expansion into additional indications provide opportunities for revenue growth despite domestic price pressures.

Frequently Asked Questions

1. When is the patent for NDC 00143-9273 expected to expire, and how will it affect pricing?
Patent expiry for biologics typically occurs 12 years after FDA approval. Once the patent expires, biosimilar competitors can enter the market, often leading to significant price reductions, sometimes 20–40% below originator prices.

2. How do biosimilars impact the pricing of the original drug?
Biosimilars increase competition, leading to downward pressure on prices through negotiated discounts, increased market share of lower-cost options, and payer incentives to favor biosimilars over the brand-name product.

3. Are there regulatory barriers that could delay biosimilar market entry for this drug?
Yes. Patent litigation, regulatory approval complexities, and market dynamics can delay biosimilar entry, temporarily preserving higher prices for the original drug.

4. What factors could accelerate or decelerate price declines in this market?
Market access strategies, clinical differentiation, regulatory developments, and payer preferences influence the pace of price decline. Continued demonstration of clinical superiority or added value can mitigate price erosion.

5. How should investors assess future revenue prospects for drugs like NDC 00143-9273?
Investors should analyze patent timelines, biosimilar pipeline developments, evolving reimbursement policies, and global market expansion opportunities to estimate long-term revenue potential.


References

[1] U.S. Food & Drug Administration. "Biologics Price Competition and Innovation Act (BPCIA)." 2010.
[2] IQVIA. "Healthcare Market Outlook: Biologics & Biosimilars." 2022.
[3] CMS. "Part B Drug Pricing & Reimbursement Policies." 2023.
[4] EvaluatePharma. "Global Pharma Market & Pricing Trends." 2022.
[5] FDA. "Biosimilar Product Development and Regulatory Considerations." 2021.


This analysis emphasizes data-driven insights into the current market landscape and future pricing strategies for NDC 00143-9273, aiming to support strategic planning and investment decision-making.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.